Screener
Aurinia Pharmaceuticals AUPH Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Restructuring | — | 114 | — | 1,647 |
| Other (income) expense, net | (6,234) | 9,246 | (5,955) | 13,675 |
| Total operating expenses | 36,879 | 49,925 | 73,162 | 90,543 |
| Income from operations | 46,341 | 20,083 | 87,763 | 41,930 |
| Interest income | 3,393 | 3,190 | 6,908 | 6,759 |
| Interest expense | (948) | (1,117) | (1,960) | (2,184) |
| Net income before income taxes | 48,786 | 22,156 | 92,711 | 46,505 |
| Income tax expense | 11,372 | 643 | 20,942 | 1,648 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's operating income?
- Aurinia Pharmaceuticals (AUPH) reported operating income of $46.34M in Q2 2026.
- How has Aurinia Pharmaceuticals's operating income changed year-over-year?
- Aurinia Pharmaceuticals's operating income increased by 130.7% year-over-year, from $20.08M to $46.34M.
- What is the long-term trend for Aurinia Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's operating income has grown at a -12.7% compound annual growth rate (CAGR), from -$180.74M to $104.91M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Aurinia Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude